Intralymphatic immunotherapy with the diabetes vaccine Diamyd® explained


Diamyd® is a novel antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an activator of the immune system involved in the pathology of autoimmune diabetes. By preventing the autoimmune destruction of insulin producing cells, Diamyd® has the potential to significantly reduce the complications of type 1 diabetes and LADA. Diamyd® is in Phase IIb clinical development.

Bädda in

Dela det här videoklippet

Om oss

Diamyd Medical är ett diabetesbolag verksamt inom läkemedelsutveckling. Två sjukdomsmodifierande behandlingar utvecklas, den antigenspecifika immunoterapin Diamyd® och den orala regenerativa och immunmodulerande terapin Remygen®.

Prenumerera